"The national vaccination strategy provides, among other things, the training of supervisors of the vaccination campaign which will begin this week, knowing that these trainers will be called upon to train, in turn, other people at the local level," said Fourar, on Channel II of the National Radio.
While reiterating that this campaign will be "started before the end of January in progress," Fourar recalled that Algeria will receive the first batch of Russian Sputnik V vaccine (500,000 doses), which will be administered "obligatorily in 2 doses, for the same person with an interval of 21 days."
"Otherwise, this vaccine will have no effect since each dose provides only 50% immunity against the virus," he added, saying that health workers will be the first category of the population to benefit from it, followed by the various security forces, citizens aged 65 years and older and then the chronically ill people.
"Finally, the entire population aged 18 years and over will benefit, as the clinical trials undertaken around the world to date have not involved those below this age group and pregnant women," he argued, before insisting on the criteria of "safety, efficacy and cold chain" on which Algeria has based its choice of vaccines, In addition to Sputnik V, the Chinese vaccine, for which "negotiations are ongoing regarding the dose to be imported," he noted, noting that the country "will be able to use other vaccines if necessary, given the global tension over this product.
"Algeria has opted for vaccines that are safe, with good safety and the fewest side effects, but it should also be noted that the vaccination campaign will last a year or more. As a result, no country can carry out its vaccination campaign with a single vaccine.
As far as we are concerned, whenever the vaccine arrives, we will continue the campaign," he said, recommending "a minimum of 60 to 70 percent vaccination coverage to succeed in stopping the circulation of the virus.